This 21-minute episode of the Journal of Clinical Oncology Podcast features host Dr. Davide Soldato interviewing Dr. Nadine Tung about her secondary analysis of the EA1181/CompassHER2 trial. The discussion centers on pathologic complete response (pCR) rates achieved with neoadjuvant THP (taxane, trastuzumab, and…
Worth it if you are an oncologist, oncology fellow, or researcher treating HER2-positive breast cancer and want to understand which patients benefit most from neoadjuvant THP based on recent trial data.